US Broker Ratings

Ligand Pharmaceuticals (LGND) Stock Analysis: A Biotech Giant with Strong Buy Ratings and a 9.6% Upside Potential

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), a prominent player in the biotechnology industry, has captured investor attention with its robust portfolio and promising growth metrics. With a market capitalization of $6.26..

Disc Medicine, Inc. (IRON) Stock Analysis: Potential Upside Sparks Investor Interest Amid Biotech Innovations

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company, has drawn significant attention in the investment community with its innovative approach to tackling serious hematologic diseases. With a market cap..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Unveiling a 64% Potential Upside

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company entrenched in the healthcare sector, is capturing investor attention with its promising developments in the biotechnology industry. Headquartered in Foster City, California,..

Agios Pharmaceuticals (AGIO): Investor Outlook Reveals a Promising 38% Upside Potential

Agios Pharmaceuticals, Inc. (AGIO), a prominent player in the biotechnology sector, is capturing the attention of investors with its robust pipeline and promising growth potential. Headquartered in Cambridge, Massachusetts, Agios..

Guardian Pharmacy Services, Inc (GRDN) Stock Analysis: Exploring a 22% Upside Potential

Guardian Pharmacy Services, Inc. (GRDN), a notable player in the healthcare sector specializing in medical care facilities, is grabbing investor attention with its promising upside potential of 22.38%. This Atlanta-based..

Immunovant, Inc. (IMVT) Investor Outlook: Analyzing the 45.94% Upside Potential

Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biotechnology company, is capturing investor attention with its promising 45.94% upside potential. Specializing in developing targeted therapies for autoimmune diseases, the company is strategically..

Twist Bioscience Corporation (TWST) Stock Analysis: Navigating a 23.2% Revenue Growth in a Challenging Market

Twist Bioscience Corporation (TWST), a prominent player in the biotechnology sector, has captured the attention of investors with its significant revenue growth of 23.2%, despite a challenging financial landscape. Specializing..

Concentra Group Holdings (CON): Investor Outlook Reveals 15.95% Upside Potential

For investors eyeing the healthcare sector, Concentra Group Holdings Parent (CON) presents an intriguing opportunity. As a key player in the medical care facilities industry, Concentra has established a robust..

Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook Reveals 38.45% Potential Upside

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focusing on the development and commercialization of treatments for central nervous system (CNS) diseases, has captured the attention of investors with a..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Tapping into a 143.64% Potential Upside

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), a prominent player in the biotechnology sector, is capturing investor attention with its promising portfolio of treatments for rare diseases. With a market capitalization of..

Acadia Healthcare (ACHC) Stock Analysis: Navigating Market Headwinds with Potential 21% Upside

Acadia Healthcare Company, Inc. (NASDAQ: ACHC), a prominent provider of behavioral healthcare services, finds itself at a pivotal moment. With a market capitalization of $2.6 billion, Acadia operates in the..

Ascentage Pharma Group Internat (AAPG) Stock Analysis: Exploring a Potential 216.49% Upside

Ascentage Pharma Group International (AAPG), a clinical-stage biotechnology company based in Suzhou, China, is garnering significant attention from investors due to its promising pipeline of therapies for cancer, chronic hepatitis..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Eye-Catching Growth with a 29.54% Potential Upside

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is catching the attention of investors with its impressive potential upside of 29.54%. As a commercial-stage biopharmaceutical company, Tarsus is focused on developing innovative solutions..

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: A Closer Look at a Potential 29.95% Upside for Investors

For investors keeping an eye on the healthcare sector, LeMaitre Vascular, Inc. (NASDAQ: LMAT) presents an intriguing opportunity. This Burlington, Massachusetts-based company, with a market capitalization of $1.88 billion, specializes..

Surgery Partners, Inc. (SGRY) Stock Analysis: Eyeing a 28.10% Upside with Solid Analyst Ratings

Surgery Partners, Inc. (NASDAQ: SGRY), a key player in the U.S. healthcare sector, is catching the attention of investors with its potential for a notable 28.10% upside. As a prominent..

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Navigating High Growth with Strategic Clinical Trials

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), a biotechnology company specializing in therapeutics for rare endocrine diseases, is drawing attention in the healthcare sector with its impressive revenue growth figures and strategic..

Warby Parker Inc. (WRBY) Stock Analysis: A 23.53% Potential Upside Amidst Strong Buy Ratings

Warby Parker Inc. (NYSE: WRBY), a prominent player in the healthcare sector’s medical instruments and supplies industry, has carved out a niche in the eyewear market with its innovative retail..

ICU Medical, Inc. (ICUI)

⚠️ No article content returned.

..

NovoCure Limited (NVCR) Stock Analysis: Unpacking a Potential 71% Upside in the Medical Device Sector

NovoCure Limited (NASDAQ: NVCR) is a prominent player in the medical device sector, specializing in innovative oncology solutions. Headquartered in Baar, Switzerland, NovoCure has carved out a niche in the..

QuidelOrtho Corporation (QDEL) Stock Analysis: A Look at the 35% Potential Upside

QuidelOrtho Corporation (QDEL) is a notable player in the healthcare sector, specializing in medical devices. Based in San Diego, California, the company has carved out a niche in providing diagnostic..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds